中國生物製藥與阿斯利康籤呼吸系統藥物獨家授權協議，金額最高達19億美元

路透中文

07/08

<a href="https://laohu8.com/S/01177">中國生物製藥</a>與<a href="https://laohu8.com/S/AZN">阿斯利康</a>籤呼吸系統藥物獨家授權協議，金額最高達19億美元

路透上海7月8日 - 中國生物製藥1177.HK周三公告稱，附屬公司正大天晴藥業已與阿斯利康AZN.L就集團自主研發的PDE3/4抑制劑（研發代號：TQC3721）訂立獨家授權協議，合計金額最高可達19億美元。

根據協議條款，該集團將授予阿斯利康在中國以外地區開發、生產及商業化TQC3721的獨家許可。阿斯利康還將獲得TQC3721特定開發方案的全球獨家許可
該集團有權獲得2億美元的首付款，以及潛在開發、監管及銷售里程碑付款，合計最高可達19億美元，同時還將獲得基於TQC3721年度淨銷售額的最高可達雙位數百分比的分級特許權使用費
TQC3721是該集團自主研發的一款具備顯著差異化優勢的吸入式PDE3/4雙重抑制劑，在多個呼吸系統適應症中具備同類最佳潛力
協議的生效以慣常的交割條件為前提，包括取得相關監管部門的批准

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/news/2649554869"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649554869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649554869?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-08 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649554869","market":"us","top_or_hot":-1,"title":"中國生物製藥與阿斯利康籤呼吸系統藥物獨家授權協議，金額最高達19億美元","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/01177\">中國生物製藥</a>與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>籤呼吸系統藥物獨家授權協議，金額最高達19億美元</title></head><body><p><span>路透上海7月8日</span><span> - </span>中國生物製藥<span>1177.HK</span>周三公告稱，附屬公司正大天晴藥業已與阿斯利康<span>AZN.L</span>就集團自主研發的PDE3/4抑制劑（研發代號：TQC3721）訂立獨家授權協議，合計金額最高可達19億美元。</p><ul><li><p>根據協議條款，該集團將授予阿斯利康在中國以外地區開發、生產及商業化TQC3721的獨家許可。阿斯利康還將獲得TQC3721特定開發方案的全球獨家許可</p></li><li><p>該集團有權獲得2億美元的首付款，以及潛在開發、監管及銷售里程碑付款，合計最高可達19億美元，同時還將獲得基於TQC3721年度淨銷售額的最高可達雙位數百分比的分級特許權使用費</p></li><li><p>TQC3721是該集團自主研發的一款具備顯著差異化優勢的吸入式PDE3/4雙重抑制劑，在多個呼吸系統適應症中具備同類最佳潛力</p></li><li><p>協議的生效以慣常的交割條件為前提，包括取得相關監管部門的批准</p></li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中國生物製藥與阿斯利康籤呼吸系統藥物獨家授權協議，金額最高達19億美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中國生物製藥與阿斯利康籤呼吸系統藥物獨家授權協議，金額最高達19億美元\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-07-08 08:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/01177\">中國生物製藥</a>與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>籤呼吸系統藥物獨家授權協議，金額最高達19億美元</title></head><body><p><span>路透上海7月8日</span><span> - </span>中國生物製藥<span>1177.HK</span>周三公告稱，附屬公司正大天晴藥業已與阿斯利康<span>AZN.L</span>就集團自主研發的PDE3/4抑制劑（研發代號：TQC3721）訂立獨家授權協議，合計金額最高可達19億美元。</p><ul><li><p>根據協議條款，該集團將授予阿斯利康在中國以外地區開發、生產及商業化TQC3721的獨家許可。阿斯利康還將獲得TQC3721特定開發方案的全球獨家許可</p></li><li><p>該集團有權獲得2億美元的首付款，以及潛在開發、監管及銷售里程碑付款，合計最高可達19億美元，同時還將獲得基於TQC3721年度淨銷售額的最高可達雙位數百分比的分級特許權使用費</p></li><li><p>TQC3721是該集團自主研發的一款具備顯著差異化優勢的吸入式PDE3/4雙重抑制劑，在多個呼吸系統適應症中具備同類最佳潛力</p></li><li><p>協議的生效以慣常的交割條件為前提，包括取得相關監管部門的批准</p></li></ul></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中國生物製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nL4T439209:1","article_id":"2649554869","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649554869","pubTimestamp":1783469944,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"中國生物製藥與阿斯利康籤呼吸系統藥物獨家授權協議，金額最高達19億美元路透上海7月8日-中國生物製藥1177.HK周三公告稱，附屬公司正大天晴藥業已與阿斯利康AZN.L就集團自主研發的PDE3/4抑制劑訂立獨家授權協議，合計金額最高可達19億美元。根據協議條款，該集團將授予阿斯利康在中國以外地區開發、生產及商業化TQC3721的獨家許可。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01177":"中国生物制药","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK1589":"北水核心资产","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0960981461.USD":"BNP PARIBAS EUROPE GROWTH \"C\" (USDHDG) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0963555726.SGD":"Blackrock European Fund A2 SGD-H","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU0526926950.USD":"贝莱德欧洲基金","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0171293334.USD":"贝莱德英国基金A2","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK1191":"制药","AZN.UK":"阿斯利康制药","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0827474353.SGD":"Allianz Europe Equity Growth Cl AT Acc H2-SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0957799991.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"ZUH\" (USDHDG) ACC","LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","03165":"华夏欧优股对冲","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0882574055.USD":"富达全球健康医疗A ACC","LU1273509221.SGD":"Fidelity European Dynamic Growth A-ACC-SGD (hedged)","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0171276677.USD":"BGF EUROPEAN SPECIAL SITUATIONS \"A2\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC"},"translate_title":"China Biopharmaceuticals and AstraZeneca sign an exclusive licensing agreement for respiratory drugs with a maximum amount of $1.9 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9,"03165":0.6,"AZN.UK":0.9},"content_text":"<a href=\"https://laohu8.com/S/01177\">中國生物製藥</a>與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>籤呼吸系統藥物獨家授權協議，金額最高達19億美元路透上海7月8日 - 中國生物製藥1177.HK周三公告稱，附屬公司正大天晴藥業已與阿斯利康AZN.L就集團自主研發的PDE3/4抑制劑（研發代號：TQC3721）訂立獨家授權協議，合計金額最高可達19億美元。根據協議條款，該集團將授予阿斯利康在中國以外地區開發、生產及商業化TQC3721的獨家許可。阿斯利康還將獲得TQC3721特定開發方案的全球獨家許可該集團有權獲得2億美元的首付款，以及潛在開發、監管及銷售里程碑付款，合計最高可達19億美元，同時還將獲得基於TQC3721年度淨銷售額的最高可達雙位數百分比的分級特許權使用費TQC3721是該集團自主研發的一款具備顯著差異化優勢的吸入式PDE3/4雙重抑制劑，在多個呼吸系統適應症中具備同類最佳潛力協議的生效以慣常的交割條件為前提，包括取得相關監管部門的批准","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}